Adolescents and adults with Fontan circulation: insights from the PREpArE-Fontan registry.

Søndergaard, Lars; Aboulhosn, Jamil; d'Udekem, Yves; Faure, Céline; Franklin, Wayne J; Hager, Alfred; Kim, Yuli Y; Muros-Le Rouzic, Erwan; Rosenberg, Daniel; Schwerzmann, Markus; Clift, Paul (2022). Adolescents and adults with Fontan circulation: insights from the PREpArE-Fontan registry. Cardiology in the young, 32(4), pp. 597-605. Cambridge University Press 10.1017/S1047951121002791

Preview

Text PREPARE_manuscript_Cardiology_in_the_Young_2021.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (667kB) | Preview

The Patient Registry for Adolescents and Adults with Stable Fontan Circulation aims to describe a contemporary cohort of Fontan patients who could be eligible for a clinical trial investigating macitentan, an endothelin receptor antagonist. This international, non-interventional, multicentre, cross-sectional, observational registry enrolled patients with "stable" Fontan circulation ≥10 years following extra-cardiac conduit or lateral tunnel procedure. Main exclusion criteria were NYHA functional class IV, reoperation of Fontan circulation, or signs of disease worsening. Patient characteristics at enrolment are described; available data were collected during a single registration visit. Of the 266 screened patients, 254 were included in this analysis. At enrolment, median (interquartile range) age was 24 (20;30) years, 37%/63% of patients were from the USA/Europe, 54% were male, 54%/47% had undergone extra-cardiac conduit/lateral tunnel procedures, and 95% were in NYHA functional class I or II. History of arrhythmia was more common in older patients and patients with lateral tunnel; overall prevalence was 19%. Most laboratory values were within the normal range but mean creatinine clearance was abnormally low (87.7 ml/min). Angiotensin-converting enzyme inhibitors were used by 48% of patients and their use was associated with creatinine clearance <90 ml/min (p = 0.007), as was Fontan completion at an older age (p = 0.007). 53.4% of patients had clinical characteristics that could potentially meet an endothelin receptor antagonist trial's eligibility criteria. The PREpArE-Fontan registry describes a cohort of patients who could potentially participate in an endothelin receptor antagonist trial and identified early subtle signs of Fontan failure, even in "stable" patients.

Interest & Impact

Downloads

69 since deposited on 08 Feb 2022
31 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item